Don Hayes1, Heidi M Mansour. 1. Advanced Lung Disease and Lung Transplant Programs, C424 University of Kentucky Medical Center, 800 Rose Street, Lexington, KY 40536, USA. don.hayes@uky.edu
Abstract
STUDY OBJECTIVES: The aim of this study was to determine the effects of an antibiotic strategy with intravenous (IV) continuous infusion of a β-lactam (CIBL) antibiotic and high-dose extended-interval (HDEI) tobramycin upon outcomes in patients with cystic fibrosis (CF) requiring invasive mechanical ventilation (IMV) for acute respiratory failure. DESIGN: The study was a retrospective review from June 1, 2006, to December 1, 2010, of patients at a university hospital with an adult CF center. RESULTS: The study population included adult CF patients requiring IMV. A total of 15 hospitalizations with IMV episodes were reviewed, involving 10 adult (31.4 ± 11.1 years) CF patients with end-stage lung disease (FEV(1) = 23.6 ± 7.8% predicted) and malnutrition (body mass index = 20.5 ± 3.1). Each patient survived to discharge and to follow-up 6 months later without the need for lung transplantation during the study period. CONCLUSIONS: A novel antibiotic strategy with a CIBL antibiotic and HDEI tobramycin improved survival in a small cohort of critically ill CF patients with end-stage lung disease and malnutrition requiring IMV.
STUDY OBJECTIVES: The aim of this study was to determine the effects of an antibiotic strategy with intravenous (IV) continuous infusion of a β-lactam (CIBL) antibiotic and high-dose extended-interval (HDEI) tobramycin upon outcomes in patients with cystic fibrosis (CF) requiring invasive mechanical ventilation (IMV) for acute respiratory failure. DESIGN: The study was a retrospective review from June 1, 2006, to December 1, 2010, of patients at a university hospital with an adult CF center. RESULTS: The study population included adult CFpatients requiring IMV. A total of 15 hospitalizations with IMV episodes were reviewed, involving 10 adult (31.4 ± 11.1 years) CFpatients with end-stage lung disease (FEV(1) = 23.6 ± 7.8% predicted) and malnutrition (body mass index = 20.5 ± 3.1). Each patient survived to discharge and to follow-up 6 months later without the need for lung transplantation during the study period. CONCLUSIONS: A novel antibiotic strategy with a CIBL antibiotic and HDEI tobramycin improved survival in a small cohort of critically ill CFpatients with end-stage lung disease and malnutrition requiring IMV.
Authors: William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191
Authors: R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel Journal: Eur J Clin Microbiol Infect Dis Date: 1989-10 Impact factor: 3.267
Authors: R Padoan; W Cambisano; D Costantini; R M Crossignani; M L Danza; G Trezzi; A Giunta Journal: Pediatr Infect Dis J Date: 1987-07 Impact factor: 2.129
Authors: Martijn G Slieker; Josephus P J van Gestel; Harry G M Heijerman; Gerdien A Tramper-Stranders; Ferdinand Teding van Berkhout; Cornelis K van der Ent; Nicolaas J G Jansen Journal: Intensive Care Med Date: 2006-03-02 Impact factor: 17.440
Authors: Don Hayes; Benjamin T Kopp; Thomas J Preston; Stephen Kirkby; Joseph D Tobias; Thomas J Papadimos; Bryan A Whitson Journal: Int J Clin Exp Med Date: 2014-05-15
Authors: Alexan I Gomez; Maria F Acosta; Priya Muralidharan; Jason X-J Yuan; Stephen M Black; Don Hayes; Heidi M Mansour Journal: Pulm Pharmacol Ther Date: 2020-10-31 Impact factor: 3.410